Short Interest in enGene Holdings Inc. (NASDAQ:ENGNW) Declines By 96.7%

enGene Holdings Inc. (NASDAQ:ENGNW) was the recipient of a significant drop in short interest in January. As of January 31st, there was short interest totalling 100 shares, a drop of 96.7% from the January 15th total of 3,000 shares. Based on an average daily volume of 3,100 shares, the days-to-cover ratio is currently 0.0 days.

enGene Stock Up 3.8 %

Shares of ENGNW opened at $1.10 on Thursday. enGene has a 1 year low of $0.42 and a 1 year high of $6.50. The company has a 50 day simple moving average of $0.98 and a two-hundred day simple moving average of $1.27.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.